Hi Sherlock57,

Thanks for making the point about Brian Brothen. I do see in the press release dated November 23rd that Nader singled him out for his efforts in recruiting for CD12.

My memory has gotten fuzzy over the years but I could swear that I remember during one of the many investor calls that Nader acknowledged Dr. Agresti as being instrumental in filling the second half of enrollment but I could be mis-remembering.

In any event, I do believe that it was the concerted push to enroll that allowed Cytodyn to further educate clinicians about Leronlimab and possibly help to target its application to those more in need (i.e. critical vs. severe patients). This is all just theory though but it seems to make sense in light of the facts we know.